Axsome enters $570M credit facility with Blackstone, retires Hercules loan

Axsome Therapeutics, Inc.

New $570M facility includes a $500M term loan (SOFR+4.75%) and a $70M revolver (SOFR+4.00%).
Initially drew $120M to repay existing Hercules term loan; up to $250M additional draws available at company's option.
Facility matures May 2030; 60-month interest-only period; expects significant reduction in interest expense.
Blackstone also purchased $15M of common stock at $107.14 per share in a concurrent private placement.
Company cites improved cost of capital and expanded credit capacity to support CNS pipeline growth.

item 1.01 item 1.02 item 2.03 item 3.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.